For many Korean biotech ventures, the clinical development phase remains the most formidable challenge in drug development. Insufficient experience with regulatory frameworks and clinical trial design continues to result in preventable failures — and BXPLANT was founded to change that.
BXPLANT, a clinical consulting startup established in 2024, operates as a CDRO (Clinical Development & Research Organization) — providing both strategic advisory and operational execution across the full continuum of pharmaceutical and biotech development. The company supports clients from clinical strategy formulation through CRO collaboration, serving as a “clinical navigation system” for biotech ventures navigating complex development pathways.
“Many biotech ventures lack the organizational infrastructure and experience to formulate a sound clinical strategy. We step in to design that strategy and identify the most efficient development pathway.”
— Minkeun Jo, CEO, BXPLANT
Failing to Stop Is Also a Failure
One of the most critical — and frequently overlooked — aspects of clinical development is knowing when to adapt or discontinue a trial. BXPLANT has observed numerous cases where clearly underpowered or misdirected studies were allowed to proceed for years without protocol amendment, resulting in costly, avoidable failures.
“We have seen studies where failure was predictable from the outset, yet they continued for two years without a single protocol modification,” said CEO Jo. “An IND approval does not mean the protocol is fixed. There is always room for adaptive refinement — but too few biotech companies take advantage of this.”
“Drug development is a decade-long endeavor. Knowing when and how to change course — or when to stop — is itself a critical strategic decision.”
— Minkeun Jo, CEO, BXPLANT
The underlying issue, according to BXPLANT, is that many companies place undue emphasis on the act of initiating a clinical trial rather than on the quality of its design. “Starting a trial quickly is not the goal — designing it correctly is,” said Jo. “Efficient trial design reduces overall cost while meaningfully improving the probability of success.”
China’s Rise and the Urgency of Clinical Efficiency
The competitive stakes in global drug development have intensified considerably, driven in large part by the rapid emergence of Chinese biopharmaceutical companies backed by substantial capital and mature clinical infrastructure.
“A significant share of recent global licensing deals now originate from Chinese companies,” said CEO Jo. “This is underpinned by a robust CRO industry and deep research infrastructure. Drug development is not solely a function of scientific capability — the clinical and nonclinical infrastructure that supports it must grow in parallel.”
In Korea, the relatively modest scale of research support infrastructure has led many biotech ventures to rely heavily on overseas CROs — an approach that adds cost, complexity, and timeline risk. BXPLANT believes the answer lies in smarter, more efficient clinical strategy rather than simply greater spend.
Bridging the Pharma–Biotech Perspective Gap
Beyond operational support, BXPLANT plays a critical role in aligning the often divergent priorities of large pharmaceutical companies and early-stage biotech ventures. “Pharma companies first ask whether a molecule can become a drug — and ultimately whether it can generate returns,” said Jo. “Biotech ventures, on the other hand, tend to focus on efficacy signals and near-term investment potential. Our role is to close that gap and build development strategies that are viable in the actual marketplace.”
“The fundamental principles of clinical development do not change significantly across disease areas or modalities. Our strength lies in applying those principles broadly — rather than limiting ourselves to a single therapeutic domain.”
— Heesun Kim, CEO, BXPLANT
Looking ahead, BXPLANT aims to evolve beyond consulting into a fully integrated clinical development platform — supporting not only pharmaceutical new drug developers but also digital therapeutic and medical device companies navigating increasingly complex regulatory environments.
“We want to be the navigation system that ensures biotech ventures never lose their way during clinical development,” said CEO Jo. “Through rapid, efficient clinical strategy, we are committed to strengthening the global competitiveness of Korea’s biopharmaceutical industry.”
source : “Press Coverage | Clinical Trial Design Determines the Fate of New Drugs”, Eun-Kyung Na, Pharm Edaily, 2026.03.13., https://pharm.edaily.co.kr/news/read?newsId=03024166645382992
